Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs

Vaccine

Volumn 29, Issue 6, 2011, Pages 1248-1257

  Jiang, Xiaohong ^a   Dalebout, Tim J ^a   Bredenbeek, Peter J ^a   Carrion, Ricardo ^b   Brasky, Kathleen ^b   Patterson, Jean ^b   Goicochea, Marco ^c   Bryant, Joseph ^c   Salvato, Maria S ^c   Lukashevich, Igor S ^c,d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Lassa Fever; Recombinant vaccines; Yellow Fever; YF17D vaccine

Indexed keywords

LASSA VIRUS GLYCOPROTEIN GP1; LASSA VIRUS GLYCOPROTEIN GP2; NONSTRUCTURAL PROTEIN 1; PLASMID DNA; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VECTOR; YELLOW FEVER VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; E VIRUS GENE; EXPERIMENTAL GUINEA PIG; FEMALE; GENE EXPRESSION; GENE INSERTION; GENETIC STABILITY; IMMUNE RESPONSE; LASSA FEVER; LASSA VIRUS; MOLECULAR CLONING; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS GENE; VIRUS RECOMBINANT;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GENETIC VECTORS; GUINEA PIGS; LASSA FEVER; MICE; MICE, INBRED CBA; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; YELLOW FEVER VACCINE;

EID: 78751611790     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.079     Document Type: Article

References (67)

1. Galbraith S.E., Barrett A.D.T. Yellow fever. Vaccines for biodefense and emerging and neglected diseases 2009, 753-785. Academic Press/Elsevier, Amsterdam, The Netherlands. A.D.T. Barrett, L.R. Stanberry (Eds.).
2. Monath T.P. Yellow fever vaccine. Expert Rev Vaccines 2005, 4:553-574.
3. Hayes E.B. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 2007, 101:967-971.
4. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26:6077-6082.
5. Silva M.L., Espirito-Santo L.R., Martins M.A., Silveira-Lemos D., Peruhype-Magalhaes V., Caminha R.C., et al. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol 2010, 17:118-126.
6. Barba-Spaeth G., Longman R.S., Albert M.L., Rice C.M. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 2005, 202:1179-1184.
7. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006, 203:413-424.
8. Palmer D.R., Fernandez S., Bisbing J., Peachman K.K., Rao M., Barvir D., et al. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol 2007, 88:148-156.
9. Akondy R.S., Monson N.D., Miller J.D., Edupuganti S., Teuwen D., Wu H., et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009, 183:7919-7930.
10. Martins MÂ, Silva M.L., Elói-Santos S.M., Ribeiro J.G.L., Peruhype-Magalhães V., Marciano A.P.V., et al. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine 2008, 26:1173-1184.
11. Martins M.Â., Silva M.L., Marciano A.P.V., Peruhype-Magalhães V., Eloi-Santos S.M., Ribeiro J.G.L., et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?. Clin Exp Immunol 2007, 148:90-100.
12. Santos A.P., Matos D.C.S., Bertho A.L., Mendonça S.C.F., Marcovistz R. Detection of TH1/TH2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. Cytokine 2008, 42:152-155.
13. Miller J.D., van der Most R.G., Akondy R.S., Glidewell J.T., Albott S., Masopust D., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28:710-722.
14. Gaucher D., Therrien R., Kettaf N., Angermann B.R., Boucher G., Filali-Mouhim A., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008, 205:3119-3131.
15. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10:116-125.
16. Monath T.P. Yellow fever vaccine. Vaccines 2004, 1095-1176. Saunders. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
17. Monath T.P. Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull Soc Pathol Exot 2006, 99:341-347.
18. WHO The yellow fever initiative, 2007 2007, WHO, Geneva, [www.who.int/csr/disease/yellowfev/introduction/en/index/html].
19. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
20. Bonaldo M.C., Garratt R.C., Caufour P.S., Freire M.S., Rodrigues M.M., Nussenzweig R.S., et al. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J Mol Biol 2002, 315:873-885.
21. Bonaldo M.C., Garratt R.C., Marchevsky R.S., Coutinho E.S.F., Jabor A.V., Almeida L.F.C., et al. Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface. J Virol 2005, 79:8602-8613.
22. Tao D., Barba-Spaeth G., Rai U., Nussenzweig V., Rice C.M., Nussenzweig R.S. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J Exp Med 2005, 201:201-209.
23. Stoyanov C.T., Boscardin S.B., Deroubaix S., Barba-Spaeth G., Franco D., Nussenzweig R.S., et al. Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine 2010, 28:4644-4652.
24. Khan S.H., Goba A., Chu M., Roth C., Healing T., Marx A., et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res 2008, 78:103-115.
25. McCormick J.B., Fisher-Hoch S.P. Lassa fever. Curr Top Microbiol Immunol 2002, 262:75-109.
26. Anonymous: W.H.O. Update on Lassa fever in West Africa. Weekly Epidemiol Record 2005, 80:86-88.
27. Richmond J.K., Baglole D. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 2003, 327:1271-1275.
28. Fichet-Calvet E, Rogers DJ. Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis 2009;3, doi:e38810.31371/journal.pntd.0000388.
29. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002, 287:2391-2405.
30. Fisher-Hoch S.P., Hutwagner L., Brown B., McCormick J.B. Effective vaccine for Lassa fever. J Virol 2000, 74:6777-6783.
31. Fisher-Hoch S.P., McCormick J.B. Lassa fever vaccine. Expert Rev Vaccines 2004, 3:103-111.
32. Lukashevich I.S., Stelmakh T.A., Golubev V.P., Stchesljenok E.P., Lemeshko N.N. Ribonucleic acids of Machupo and Lassa viruses. Arch Virol 1984, 79:189-203.
33. Lukashevich I.S., Salvato M.S. Lassa virus genome. Curr Genomics 2006, 7:351-379.
34. Lukashevich I., Djavani M., Shapiro K., Sanchez A., Ravkov E., Nichol S., et al. The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250kDa protein with monospecific antiserum. J Gen Virol 1997, 78:547-551.
35. Djavani M., Lukashevich I.S., Sanchez A., Nichol S.T., Salvato M.S. Completion of the Lassa fever virus sequence and identification of a RING finger open reading frame at the L RNA 5' end. Virology 1997, 235:414-418.
36. Auperin D.D., Sasso D.R., McCormick J.B. Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. Virology 1986, 154:155-167.
37. Clegg J.C., Wilson S.M., Oram J.D. Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products. Virus Res 1991, 18:151-164.
38. Lenz O., ter Meulen J., Klenk H-D., Seidah N.G., Garten W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. PNAS 2001, 98:12701-12705.
39. Feldmann H, Geisbert TW, Jahrling PB, Klenk HD, Netesov SV, Peters CJ, et al. Filoviridae. Virus taxonomy. VIIIth report of the International Committee on Taxonomy of Viruses; 2005. p. 645-53.
40. Peters C.J., Jahrling P.B., Liu C.T., Kenyon R.H., McKee K.T., Oro J.G.B. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol 1987, 134:5-68.
41. Lukashevich I.S., Patterson J., Carrion R., Moshkoff D., Ticer A., Zapata J., et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 2005, 79:13934-13942.
42. Bredenbeek P.J., Molenkamp R., Spaan W.J.M., Deubel V., Marianneau P., Salvato M.S., et al. A recombinant yellow fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006, 345:299-304.
43. Bredenbeek P.J., Kooi E.A., Lindenbach B., Huijkman N., Rice C.M., Spaan W.J.M. A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J Gen Virol 2003, 84:1261-1268.
44. Lukashevich I.S. Generation of reassortants between African arenaviruses. Virology 1992, 188:600-605.
45. Lukashevich I.S. A live reassortant vaccine for Lassa Fver. Molecular pathogenesis of hemorrhagic fever viruses 2010, 143-170. Transw Res Net, Kerala, India. E.M. Vela (Ed.).
46. Lukashevich I.S., Vela E.M. Pathogenesis of Lassa virus infection in experimental animals. Molecular pathogenesis of hemorrhagic fever viruses 2010, 101-142. Transw Res Net, Kerala, India. E.M. Vela (Ed.).
47. Salvato M.S., Lukashevich I.S. Vaccines against Lassa fever. New generation vaccines 2009, 895-904. Marcel Dekker, Inc. 4th ed. M. Myron, Levine (Eds.).
48. Pushko P., Geisbert J., Parker M., Jahrling P., Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 2001, 75:11677-11685.
49. Demby A.H., Chamberlain J., Brown D.W., Clegg C.S. Early diagnosis of Lassa fever by reverse transcription-PCR. J Clin Microbiol 1994, 32:2898-2903.
50. Bonaldo M., Mello S., Trindade G., Rangel A., Duarte A., Oliveira P., et al. Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes. Virol J 2007, 4:115.
51. McCormick J.B., Walker D.H., King I.J., Webb P.A., Elliott L.H., Whitfield S.G., et al. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am J Trop Med Hyg 1986, 35:401-407.
52. Jahrling P.B., Smith S., Hesse R.A., Rhoderick J.B. Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun 1982, 37:771-778.
53. Carrion R.J., Patterson J.L., Johnson C., Gonzales M., Moreira C.R., Ticer A., et al. A ML29 reassortant virus protects guinea pigs against a distantly-related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 2007, 25:4093-4102.
54. McAllister A., Arbetman A.E., Mandl S., Pena-Rossi C., Andino R. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J Virol 2000, 74:9197-9205.
55. Van Epps H.L. Broadening the horizons for yellow fever: new uses for an old vaccine. J Exp Med 2005, 201:165-168.
56. Bonaldo M., Garratt R.C., Caufour P.S., Freire M.S., Rodrigues M.M., Nussenzweig R.S., et al. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J Mol Biol 2002, 315:873-885.
57. Xiaowu P., Fu W.C., Guo Y.H., Zhang L.S., Xie T.P., G G.X. Construction of recombinant yellow fever virus 17D containing 2A fragment as a vaccine vector. Chin J Biotech 2006, 22:492-498.
58. Chambers TJ, Monath TP, Guirakhoo F. US6696281; 2004.
59. Rumyantsev A.A., Zhang Z-x, Gao Q-s, Moretti N., Brown N., Kleanthous H., et al. Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus. Virology 2010, 396:329-338.
60. Bonaldo M.C., Martins M.A., Rudersdorf R., Mudd P.A., Sacha J.B., Piaskowski S.M., et al. Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in Rhesus macaques. J Virol 2010, 84:3699-3706.
61. Barban V., Girerd Y., Aguirre M., Gulia S., Pétiard F., Riou P., et al. High stability of yellow fever 17D-204 vaccine: A 12-year restrospective analysis of large-scale production. Vaccine 2007, 25:2941-2950.
62. Monath T.P., Myers G.A., Beck R.A., Knauber M., Scappaticci K., Pullano T., et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 2005, 33:131-144.
63. Monath T.P., Levenbook I., Soike K., Zhang Z-X., Ratterree M., Draper K., et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in Rhesus monkeys. J Virol 2000, 74:1742-1751.
64. Receveur M., Thiébaut R., Vedy S., Malvy D., Mercié P., Bras M.L. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis 2000, 31:E7-E8.
65. Tattevin P., Depatureaux A.G., Chapplain J.M., Dupont M., Souala F., Arvieux C., et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 2004, 18:825-827.
66. Xiang J., McLinden J.H., Rydze R.A., Chang Q., Kaufman T.M., Klinzman D., et al. Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells. J Immunol 2009, 183:7860-7869.
67. Zapata JCPB, Goicochea M, Bryant J, Davis H, Pauza CD, Lukashevich IS, et al. Arenavirus vaccines in SIV-positive Rhesus macaques. ASV, 28th Meeting, Scientific Program & Abstracts, Vancouver, Canada. 2009. W7-9, p. 94.